The molecular basis for the intrinsic ISG signature we observe in mutant KRAS AALE cells differs from TE RNA-induced IFN responses in cancer cells treated with DNA methyltransferase inhibitors (Chiappinelli et al., 2015; Roulois et al., 2015), as we instead find a prominent role for broad KZNF suppression during the early stages of mutant KRAS-driven cellular transformation. The gene discussed is KRAS; the disease is cancer.